Client News

ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022

Carbios: 2022 half-year results

InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round

ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022

Destiny Pharma: Notice of R&D Update Meeting

Spexis announces positive renal impairment clinical trial results with balixafortide

CEVEC: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing

Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE